Rchr
J-GLOBAL ID：202001016447270374
Update date: Oct. 01, 2024
Tokuda Shinsaku
トクダ シンサク | Tokuda Shinsaku
Affiliation and department：
Research theme for competitive and other funds (1)：
- 2023 - 2026 Elucidation of drug resistance by the hypoxic environment adaptation mechanism in lung cancer and development of novel therapeutic strategy
Papers (31)：
-
Nobutaka Kataoka, Yuki Katayama, Tadaaki Yamada, Kenji Morimoto, Takayuki Takeda, Asuka Okada, Shinsuke Shiotsu, Yusuke Chihara, Osamu Hiranuma, Takahiro Yamada, et al. CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study. Translational lung cancer research. 2024. 13. 8. 1929-1937
-
Ryota Nakamura, Tadaaki Yamada, Shinsaku Tokuda, Kenji Morimoto, Yuki Katayama, Yohei Matsui, Soichi Hirai, Masaki Ishida, Hayato Kawachi, Ryo Sawada, et al. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer. Cancer letters. 2024. 598. 217124-217124
-
Yohei Matsui, Tadaaki Yamada, Yuki Katayama, Soichi Hirai, Ryo Sawada, Yusuke Tachibana, Masaki Ishida, Hayato Kawachi, Ryota Nakamura, Naoya Nishioka, et al. Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells. Cancer science. 2024
-
Keisuke Onoi, Tadaaki Yamada, Kenji Morimoto, Hayato Kawachi, Rei Tsutsumi, Takayuki Takeda, Asuka Okada, Nobuyo Tamiya, Yusuke Chihara, Shinsuke Shiotsu, et al. Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients. Targeted oncology. 2024
-
Masaki Ishida, Masahiro Iwasaku, Toshifumi Doi, Takeshi Ishikawa, Yusuke Tachibana, Ryo Sawada, Yuri Ogura, Hayato Kawachi, Yuki Katayama, Naoya Nishioka, et al. Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer. Cancer science. 2024
ｍore...
Professional career (1)：
Return to Previous Page
